These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29991523)

  • 1. Angiotensin receptor neprilysin inhibitors in older patients with heart failure.
    Sharkey AT; Ghafar MZ; O'Keeffe ST; Mulkerrin EC
    BMJ Evid Based Med; 2019 Feb; 24(1):5-7. PubMed ID: 29991523
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.
    Ferrari L; Sada S;
    Intern Emerg Med; 2015 Apr; 10(3):369-71. PubMed ID: 25537439
    [No Abstract]   [Full Text] [Related]  

  • 3. PARADIGM-HF--the experts' discussion.
    Jessup M; Fox KA; Komajda M; McMurray JJ; Packer M
    N Engl J Med; 2014 Sep; 371(11):e15. PubMed ID: 25184757
    [No Abstract]   [Full Text] [Related]  

  • 4. In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
    Srivastava PK; Fonarow GC
    JAMA Cardiol; 2019 Mar; 4(3):195-196. PubMed ID: 30810709
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
    Packer M; McMurray JJ; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile M; Andersen K; Arango JL; Arnold JM; Bělohlávek J; Böhm M; Boytsov S; Burgess LJ; Cabrera W; Calvo C; Chen CH; Dukat A; Duarte YC; Erglis A; Fu M; Gomez E; Gonzàlez-Medina A; Hagège AA; Huang J; Katova T; Kiatchoosakun S; Kim KS; Kozan Ö; Llamas EB; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires FJ; Refsgaard J; Rosenthal A; Senni M; Sibulo AS; Silva-Cardoso J; Squire IB; Starling RC; Teerlink JR; Vanhaecke J; Vinereanu D; Wong RC;
    Circulation; 2015 Jan; 131(1):54-61. PubMed ID: 25403646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure: another new PARADIGM in treatment for heart failure?
    Geach T
    Nat Rev Cardiol; 2015 Jan; 12(1):4. PubMed ID: 25445135
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?
    Krum H
    Circulation; 2015 Jan; 131(1):11-2. PubMed ID: 25411157
    [No Abstract]   [Full Text] [Related]  

  • 8. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neprilysin inhibition--a novel therapy for heart failure.
    Jessup M
    N Engl J Med; 2014 Sep; 371(11):1062-4. PubMed ID: 25176014
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Książczyk M; Lelonek M
    Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction.
    Bartell N; Frishman WH
    Cardiol Rev; 2017; 25(6):315-320. PubMed ID: 28984670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
    McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
    N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor-neprilysin inhibitors in heart failure: a shifting paradigm.
    Vardeny O
    Evid Based Med; 2015 Apr; 20(2):61. PubMed ID: 25659916
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neprilysin Inhibitors in Cardiovascular Disease.
    Kang G; Banerjee D
    Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
    Cannon JA; Shen L; Jhund PS; Kristensen SL; Køber L; Chen F; Gong J; Lefkowitz MP; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Eur J Heart Fail; 2017 Jan; 19(1):129-137. PubMed ID: 27868321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.